Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Chardan Capital issued their FY2026 EPS estimates for shares of Krystal Biotech in a report issued on Thursday, February 20th. Chardan Capital analyst Y. Livshits anticipates that the company will post earnings per share of $9.95 for the year. Chardan Capital currently has a “Buy” rating and a $218.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

KRYS has been the topic of several other reports. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, February 19th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Performance

KRYS opened at $187.86 on Monday. The company’s 50 day simple moving average is $157.85 and its 200 day simple moving average is $175.26. Krystal Biotech has a 1 year low of $107.50 and a 1 year high of $219.34. The stock has a market capitalization of $5.41 billion, a PE ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period last year, the company earned $0.30 earnings per share. The company’s quarterly revenue was up 116.4% on a year-over-year basis.

Institutional Trading of Krystal Biotech

Hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter valued at approximately $40,000. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $95,000. Huntington National Bank raised its stake in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares during the period. Blue Trust Inc. raised its stake in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after purchasing an additional 412 shares during the period. Finally, Covestor Ltd raised its stake in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after purchasing an additional 642 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).